U.S. markets open in 8 hours 40 minutes
  • S&P Futures

    4,168.00
    +10.25 (+0.25%)
     
  • Dow Futures

    34,359.00
    +103.00 (+0.30%)
     
  • Nasdaq Futures

    13,347.25
    +43.75 (+0.33%)
     
  • Russell 2000 Futures

    2,233.20
    +7.70 (+0.35%)
     
  • Crude Oil

    66.51
    +0.24 (+0.36%)
     
  • Gold

    1,868.00
    +0.40 (+0.02%)
     
  • Silver

    28.61
    +0.34 (+1.21%)
     
  • EUR/USD

    1.2167
    +0.0010 (+0.09%)
     
  • 10-Yr Bond

    1.6400
    0.0000 (0.00%)
     
  • Vix

    19.72
    +0.91 (+4.84%)
     
  • GBP/USD

    1.4174
    +0.0036 (+0.26%)
     
  • USD/JPY

    109.1810
    -0.0190 (-0.02%)
     
  • BTC-USD

    45,373.82
    +1,891.19 (+4.35%)
     
  • CMC Crypto 200

    1,262.61
    +64.69 (+5.40%)
     
  • FTSE 100

    7,032.85
    -10.76 (-0.15%)
     
  • Nikkei 225

    28,397.88
    +573.05 (+2.06%)
     

Could The Clearside Biomedical, Inc. (NASDAQ:CLSD) Ownership Structure Tell Us Something Useful?

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Clearside Biomedical, Inc. (NASDAQ:CLSD) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.

Clearside Biomedical is not a large company by global standards. It has a market capitalization of US$160m, which means it wouldn't have the attention of many institutional investors. In the chart below, we can see that institutions own shares in the company. Let's delve deeper into each type of owner, to discover more about Clearside Biomedical.

Check out our latest analysis for Clearside Biomedical

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Clearside Biomedical?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

Clearside Biomedical already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Clearside Biomedical, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

It would appear that 12% of Clearside Biomedical shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The company's largest shareholder is RTW Investments, LP, with ownership of 7.5%. The second and third largest shareholders are Carmignac Gestion S.A. and Bradford Whitmore, with an equal amount of shares to their name at 6.7%.

On studying our ownership data, we found that 25 of the top shareholders collectively own less than 50% of the share register, implying that no single individual has a majority interest.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Clearside Biomedical

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own some shares in Clearside Biomedical, Inc.. In their own names, insiders own US$11m worth of stock in the US$160m company. It is good to see some investment by insiders, but I usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.

General Public Ownership

The general public holds a 50% stake in Clearside Biomedical. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

Private equity firms hold a 6.0% stake in Clearside Biomedical. This suggests they can be influential in key policy decisions. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 5 warning signs for Clearside Biomedical you should be aware of, and 2 of them make us uncomfortable.

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.